MX2016017025A - Formulaciones de proteinas. - Google Patents

Formulaciones de proteinas.

Info

Publication number
MX2016017025A
MX2016017025A MX2016017025A MX2016017025A MX2016017025A MX 2016017025 A MX2016017025 A MX 2016017025A MX 2016017025 A MX2016017025 A MX 2016017025A MX 2016017025 A MX2016017025 A MX 2016017025A MX 2016017025 A MX2016017025 A MX 2016017025A
Authority
MX
Mexico
Prior art keywords
protein formulations
formulations
present disclosure
temperatures
variety
Prior art date
Application number
MX2016017025A
Other languages
English (en)
Inventor
PARK Sungae
J Mcauley Arnold
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2016017025A publication Critical patent/MX2016017025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona formulaciones sólidas de proteínas que son estables sobre una variedad de temperaturas durante períodos prolongados de tiempo. La presente descripción también proporciona los métodos para preparar y utilizar estas formulaciones.
MX2016017025A 2014-06-26 2015-06-15 Formulaciones de proteinas. MX2016017025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017560P 2014-06-26 2014-06-26
PCT/US2015/035884 WO2015200027A1 (en) 2014-06-26 2015-06-15 Protein formulations

Publications (1)

Publication Number Publication Date
MX2016017025A true MX2016017025A (es) 2017-08-08

Family

ID=53610976

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016017025A MX2016017025A (es) 2014-06-26 2015-06-15 Formulaciones de proteinas.
MX2020012893A MX2020012893A (es) 2014-06-26 2016-12-19 Formulaciones de proteinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012893A MX2020012893A (es) 2014-06-26 2016-12-19 Formulaciones de proteinas.

Country Status (8)

Country Link
US (1) US20170209582A1 (es)
EP (2) EP3160511B1 (es)
JP (4) JP6634394B2 (es)
AU (3) AU2015280480A1 (es)
CA (1) CA2952609A1 (es)
ES (1) ES2960599T3 (es)
MX (2) MX2016017025A (es)
WO (1) WO2015200027A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101994456B1 (ko) * 2017-03-15 2019-06-28 이건무 당 수액제 조성물
CA3082786A1 (en) * 2017-11-16 2019-05-23 Amgen Inc. Stable compositions of pegylated carfilzomib compounds
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
MX2022008655A (es) * 2020-01-13 2022-09-23 Aptevo Res & Development Llc Metodos y composiciones para prevenir la adsorcion de proteinas terapeuticas en componentes del sistema de administracion de farmacos.
JP7278503B2 (ja) * 2020-09-24 2023-05-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー コンシズマブの医薬製剤およびその生産方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
DK2275119T3 (da) * 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2006272804B2 (en) * 2005-07-22 2011-02-24 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CN102573792B (zh) * 2009-09-21 2014-10-15 巴克斯特国际公司 稳定化的液体和冻干的adamts13制剂
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies

Also Published As

Publication number Publication date
AU2015280480A1 (en) 2017-01-05
EP3160511A1 (en) 2017-05-03
JP6634394B2 (ja) 2020-01-22
EP3160511B1 (en) 2023-07-26
EP4285930A3 (en) 2024-02-28
JP2021178862A (ja) 2021-11-18
MX2020012893A (es) 2021-02-26
EP4285930A2 (en) 2023-12-06
WO2015200027A1 (en) 2015-12-30
JP2017519777A (ja) 2017-07-20
AU2023200296A1 (en) 2023-02-23
AU2020250182A1 (en) 2020-11-05
CA2952609A1 (en) 2015-12-30
JP2019203018A (ja) 2019-11-28
US20170209582A1 (en) 2017-07-27
ES2960599T3 (es) 2024-03-05
JP2023162442A (ja) 2023-11-08

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
SG10201809428UA (en) Insulin receptor partial agonists
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2020012893A (es) Formulaciones de proteinas.
HK1231394A1 (zh) 烯醇酶 組合物及其用途
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MY167350A (en) Fat-and-oil composition and chocolate
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
NZ744340A (en) Anti-jagged1 antibodies and methods of use
AU365961S (en) Clasp

Legal Events

Date Code Title Description
FG Grant or registration